Edgewise Therapeutics closes out surprise IPO with $202.4M raised

BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) raised $202.4 million in funding from its confidentially filed initial public offering last week, marking the maximum it could have received from the event.

The Boulder developer of genetic therapies for muscular disorders said in a statement that all 12.65 million of shares that were offered to the public were purchased, along with all 1.65 million shares that were reserved for the IPO’s underwriters to purchase at their discretion.

The company did not specify how much of that total will be deducted to cover underwriting fees and other expenses.

Edgewise kicked off the IPO on Friday…